secwatch.observer — SEC 8-K summary
======================================

Issuer:     Metagenomi Therapeutics, Inc. (MGX)
CIK:        0001785279
Form:       8-K
Filed at:   2024-08-14T23:59:59+00:00
Accession:  0000950170-24-096673
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Metagenomi declares MGX-001 DC for hemophilia A; cash $299.9M into 2027
-----------------------------------------------------------------------

- Declared MGX-001 as lead development candidate for hemophilia A; 12-month NHP data accelerated to September 2024.
- Cash, cash equivalents and marketable securities of $299.9M at June 30, 2024; runway into 2027.
- R&D expense $28.3M in Q2 2024 vs $22.7M in Q2 2023; G&A expense $8.6M vs $6.6M.
- All four Ionis Wave 1 cardiometabolic programs in lead optimization; targeting 1–2 DC nominations in 2025.
- Deprioritizing PH1 and ALS programs; pipeline guidance revised through year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/0000950170-24-096673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1785279/000095017024096673/mgx-20240814.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-096673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer